{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:32:19Z","timestamp":1782459139656,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012860","name":"Comprehensive Cancer Center at Wake Forest Baptist Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012860","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.lungcan.2025.108513","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T13:30:07Z","timestamp":1743255007000},"page":"108513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status"],"prefix":"10.1016","volume":"203","author":[{"given":"Safoa","family":"Addo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lycan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Soto-Pantoja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-7543","authenticated-orcid":false,"given":"Ericson","family":"Stoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamjeed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5794-4326","authenticated-orcid":false,"given":"Joni K.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7242-3315","authenticated-orcid":false,"given":"Jimmy","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Triozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1553-1838","authenticated-orcid":false,"given":"W. Jeffrey","family":"Petty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.lungcan.2025.108513_b0005","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.34479","article-title":"Annual report to the nation on the status of cancer, part 1: national cancer statistics","volume":"128","author":"Cronin","year":"2022","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108513_b0010","article-title":"Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: a systematic evaluation and meta-analysis","volume":"19","author":"Y","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108513_b0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","article-title":"Prevalence of poor performance status in lung cancer patients: implications for research","volume":"3","author":"Lilenbaum","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108513_b0020","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/JTO.0b013e3181d2dcd9","article-title":"Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC","volume":"5","author":"Kawaguchi","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108513_b0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1556-0864(15)30041-1","article-title":"Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase ii study of the Hellenic Cooperative Group","volume":"2","author":"Kosmidis","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108513_b0030","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/JTO.0b013e3181a9a020","article-title":"Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials","volume":"4","author":"Lilenbaum","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2025.108513_b0035","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.1200\/JCO.2022.40.16_suppl.9000","article-title":"Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 Score >\/= 50%: FDA pooled analysis","volume":"14","author":"Akinboro","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108513_b0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034010","article-title":"Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review","volume":"10","author":"Li","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.lungcan.2025.108513_b0045","article-title":"Comparative efficacy and safety of immunotherapy alone and in combination with chemotherapy for advanced non-small cell lung cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108513_b0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in non-squamous non\u2013small-cell lung cancer: 5-year outcomes from the Phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108513_b0055","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1665974","article-title":"Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis","volume":"8","author":"El-Osta","year":"2019","journal-title":"Oncoimmunology."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108513_b0060","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med."},{"issue":"24","key":"10.1016\/j.lungcan.2025.108513_b0065","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108513_b0070","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence","volume":"20","author":"de Biasi","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108513_b0075","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejps.2009.08.009","article-title":"Paclitaxel and immune system","volume":"38","author":"Javeed","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108513_b0080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/0008-5472.CAN-12-2225","article-title":"Dose-dense chemotherapy improves mechanisms of antitumor immune response","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108513_b0085","first-page":"13","article-title":"Immunotherapy of targeting MDSCs in tumor microenvironment","volume":"5","author":"Sui","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108513_b0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/vaccines4040036","article-title":"The role of myeloid-derived suppressor cells (MDSC) in cancer progression","volume":"4","author":"Umansky","year":"2016","journal-title":"Vaccines."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108513_b0095","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-0843-1","article-title":"Myeloid-derived suppressor cells\u2014new and exciting players in lung cancer","volume":"13","author":"Yang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lungcan.2025.108513_b0100","article-title":"Prognostic impact of memory CD8 (+) T cells on immunotherapy in human cancers: a systematic review and meta-analysis","author":"Jin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2025.108513_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101134","article-title":"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"EClinicalMedicine."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108513_b0110","first-page":"1349","article-title":"Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: an interim analysis","volume":"17","author":"Bonomi","year":"2019","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108513_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.esmoop.2020.100013","article-title":"Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients","volume":"6","author":"Rothschild","year":"2021","journal-title":"ESMO Open"},{"issue":"16","key":"10.1016\/j.lungcan.2025.108513_b0120","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","article-title":"Afatinib versus Erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","volume":"6","author":"Soria","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108513_b0125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/978-1-4020-6191-2_13","article-title":"The plasma membrane calcium ATPase and disease","volume":"45","author":"Tempel","year":"2007","journal-title":"Subcell Biochem."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108513_b0130","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1096\/fj.201801873R","article-title":"Substrates of P4-ATPases: beyond aminophospholipids (phosphatidylserine and phosphatidylethanolamine)","volume":"33","author":"Shin","year":"2019","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108513_b0135","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1438-8677.2009.00303.x","article-title":"Structure and putative function of NFX1-like proteins in plants","volume":"12","author":"M\u00fcssig","year":"2010","journal-title":"Plant Biol (stuttg)."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108513_b0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41420-023-01405-1","article-title":"Dual role of PID1 in regulating apoptosis induced by distinct anticancer-agents through AKT\/Raf-1-dependent pathway in hepatocellular carcinoma","volume":"9","author":"Yang","year":"2023","journal-title":"Cell Death Discov."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108513_b0145","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","article-title":"Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial","volume":"8","author":"Middleton","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"issue":"402","key":"10.1016\/j.lungcan.2025.108513_b0150","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(23)00774-2","article-title":"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre open-label randomized controlled study","volume":"5","author":"Lee","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108513_b0155","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkac013","article-title":"Immunotherapy outcomes in individuals with non\u2013small cell lung cancer and poor performance status","volume":"6","author":"Veluswamy","year":"2022","journal-title":"JNCI Cancer Spectru"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108513_b0160","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.21037\/tlcr-21-15","article-title":"First-line Immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis","volume":"10","author":"Facchinetti","year":"2021","journal-title":"Translational Lung Cancer Research."},{"key":"10.1016\/j.lungcan.2025.108513_b0165","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9011","article-title":"Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (\u2265 70 years) patients with advanced non\u2013small cell lung cancer (Energy-GFPC 06-2015 study)","author":"Lena","year":"2022","journal-title":"J Clin Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108513_b0170","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.advms.2021.07.005","article-title":"Current state of knowledge on immunotherapy in ECOG PS 2 patients. a systematic review","volume":"66","author":"Mojsak","year":"2021","journal-title":"Adv. Med. Sci."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108513_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtocrr.2023.100482","article-title":"Impact of performance status on survival outcomes and health care utilization in patients with advanced NSCLC treated with immune checkpoint inhibitors","volume":"4","author":"Meyers","year":"2023","journal-title":"JTO Clinical and Research Reports."},{"issue":"152","key":"10.1016\/j.lungcan.2025.108513_b0180","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lungcan.2020.12.027","article-title":"Immunotherapy in advanced non-small cell lung cancer patients with poor performance status: the role of clinical-pathological variables and inflammatory biomarkers","volume":"1","author":"Lobefaro","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108513_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866561","article-title":"High levels of circulating monocytic myeloid-derived suppressive-like cells are associated with the primary resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: an exploratory analysis","volume":"13","author":"Bronte","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2025.108513_b0190","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-022-00946-6","article-title":"The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis","author":"Bronte","year":"2022","journal-title":"Clin. Exp. Med."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108513_b0195","first-page":"1021","article-title":"Myeloid-derived suppressor cells in malignant melanoma","volume":"12","author":"Umansky","year":"2014","journal-title":"JDDG: J. Dtsch. Dermatol. Ges."},{"issue":"41","key":"10.1016\/j.lungcan.2025.108513_b0200","doi-asserted-by":"crossref","first-page":"17111","DOI":"10.1073\/pnas.1108121108","article-title":"Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model","volume":"108","author":"Meyer","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108513_b0205","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.29297","article-title":"Elevated Chronic Inflammatory Factors and myeloid-derived Suppressor Cells Indicate Poor Prognosis in Advanced Melanoma Patients","volume":"136","author":"Jiang","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108513_b0210","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1158\/1078-0432.CCR-13-2508","article-title":"Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A\u2013Specific T Cells","volume":"20","author":"Weide","year":"2014","journal-title":"Clin. Cancer Res."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:26:30Z","timestamp":1777782390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225004052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":42,"alternative-id":["S0169500225004052"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108513","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108513"}}